Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | PsyAI artificial intelligence system

Joseph Tucker • 24 Nov 2021
General

Joseph Tucker, PhD, CEO of Enveric Biosciences, Naples, FL, explains the ‘PsyAI’ artificial intelligence system. This AI filters through Enveric’s ‘Psybrary’ of millions of novel synthetic drug candidates to select the most ideal candidates for each new target.

Disclosures

Forward-Looking Statements

This video presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors. A discussion of these factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.

More from Joseph Tucker

2:24
Enveric Biosciences: Novel strategies to treat side effects of cancer and cancer treatment
Joseph Tucker • 24 Nov 2021
2:59
Cannabinoids for radiation dermatitis
Joseph Tucker • 24 Nov 2021
2:54
Psychedelics for cancer-related distress
Joseph Tucker • 24 Nov 2021

Related Videos

2:02
Improving treatment and care of elderly patients with CRC after surgery
Isacco Montroni • 27 Jun 2024
1:10
TU2218, a TGFβ-RI and VEGFR2 dual inhibitor, with pembrolizumab in solid tumors
Do-Youn Oh • 28 Jun 2024
0:39
Next generation CAR T-cell therapies for solid tumors
Salman Punekar • 1 Jun 2024
1:23
BASECAMP-1: a prescreening study for the EVEREST-1 and -2 trials in solid tumors
Caleb Smith • 1 Jun 2024
The content of VJOncology is intended for healthcare professionals